ReviewJournal of clinical medicine2019
Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review.European journal of nuclear medicine and molecular imaging · 2019Pooled it
- Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art.EJNMMI radiopharmacy and chemistry · 2026Review
- Folic Acid Targeting Shared Sepsis-Osteoporosis Pathogenesis: From Computational Discovery to Dynamic Binding Mechanisms.ACS omega · 2026Article
- Noninvasive in vivo deoxycytidine kinase (dCK)-PET identifies tumor-draining lymph nodes upon immune checkpoint inhibitor therapy.Npj imaging · 2026Article
- A Comprehensive Review of SSTR-Based Spect and Pet Imaging in Chronic Inflammatory and Immune-Mediated Diseases.Journal of clinical medicine · 2025Review
- Validation of a Ready-to-Use Lyophilized Kit for Labeling IL2 withJournal of clinical medicine · 2025Article
- Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity.Journal for immunotherapy of cancer · 2025Review
- Present status and future trends in molecular imaging of lymphocytes.Seminars in nuclear medicine · 2023Review
- Development of aEJNMMI research · 2022Article
- Sjögren Syndrome: New Insights in the Pathogenesis and Role of Nuclear Medicine.Journal of clinical medicine · 2022Review
- Radionuclide Imaging of Invasive Fungal Disease in Immunocompromised Hosts.Diagnostics (Basel, Switzerland) · 2021Review
- Immune cell labelling and tracking: implications for adoptive cell transfer therapies.EJNMMI radiopharmacy and chemistry · 2021Review
- Review
- Review
- Current Applications for Nuclear Medicine Imaging in Pulmonary Disease.Current pulmonology reports · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMolecular nuclear medicine plays a pivotal role for diagnosis in a preclinical phase, in genetically susceptible patients, for radio-guided surgery, for disease relapse evaluation, and for therapy decision-making and follow-up. This is possible thanks to the development of new radiopharmaceuticals to target specific biomarkers of infection, inflammation and tumour immunology.
methodsIn this review, we describe the use of specific radiopharmaceuticals for infectious and inflammatory diseases with the aim of fast and accurate diagnosis and treatment follow-up. Furthermore, we focus on specific oncological indications with an emphasis on tumour immunology and visualizing the tumour environment.
resultsMolecular nuclear medicine imaging techniques get a foothold in the diagnosis of a variety of infectious and inflammatory diseases, such as bacterial and fungal infections, rheumatoid arthritis, and large vessel vasculitis, but also for treatment response in cancer immunotherapy.
conclusionSeveral specific radiopharmaceuticals can be used to improve diagnosis and staging, but also for therapy decision-making and follow-up in infectious, inflammatory and oncological diseases where immune cells are involved. The identification of these cell subpopulations by nuclear medicine techniques would provide personalized medicine for these patients, avoiding side effects and improving therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.